Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FLINTy reception for Intercept

Although a Bloomberg report on The Lancet's publication of data from the Phase II FLINT trial of obeticholic acid in non-alcoholic steatohepatitis (NASH) largely rehashed old ground, investors hammered shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) on Friday. The stock

Read the full 399 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE